Wednesday, September 2, 2015

Blackstone to sell Catalent to Frazier Healthcare, sources say

All or part of Catalent Pharma Solutions, with facilities in Northeast Philadelphia and Mount Laurel, is about to be sold by the Blackstone Group to Frazier Healthcare, a West Coast-based venture capital firm, sources said.

Blackstone to sell Catalent to Frazier Healthcare, sources say

0 comments

All or part of Catalent Pharma Solutions, which has a big facility in Northeast Philadelphia and another in Mount Laurel, is about to be sold by the Blackstone Group to Frazier Healthcare, a West Coast-based venture capital firm, sources said.

Catalent contracts with pharmaceutical companies to manufacture and package medicine.

Neither the price of the transaction nor whether Blackstone is selling all or part of Catalent could be determined Wednesday afternoon.

A Frazier Healthcare spokesperson declined to comment when asked about the sale and how it might impact operations in this area.

A Blackstone spokesman declined comment.

A call and email to a spokesperson for Catalent were not returned.

Catalent's headquarters is in Somerset, N.J. Catalent's 427,908-square foot packaging facility on Red Lion Road in Northeast Philadelphia is the largest of the company's facilities, which touch five continents. Catalent also has a facility at that location is for development and clinical services.

Catalent has 8,200 employees, with 3,250 in North America. The Philadelphia employment numbers were not available.

In 2007, Blackstone spent about $3.3 billion to acquire Pharmaceutical Technologies and Services (PTS) from Cardinal Health, and renamed it Catalent Pharma Solutions. But the company has struggled in recent years to be profitable.

In the fiscal year ending June 30, 2011, the company reported in a Securities and Exchange Commission filing that it had a net loss of $54 million, though that was an improvement over the $289 million loss that was reported in June 2010.

In the quarter ending March 31 of this year, Catalent reported a loss of $20.8 million and a nine-month loss of $69.7 million, according to its SEC filing.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter